WallStSmart

Dyadic International Inc (DYAI)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 14565% more annual revenue ($606.42M vs $4.14M). INSM leads profitability with a -2.1% profit margin vs -134.8%. INSM earns a higher WallStSmart Score of 39/100 (F).

DYAI

Avoid

21

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DYAI0 strengths · Avg: 0/10

No standout strengths identified

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

DYAI4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$32.75M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-4.2%2/10

ROE of -4.2% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DYAI

DYAI has a balanced fundamental profile.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : DYAI

The primary concerns for DYAI are Revenue Growth, EPS Growth, Market Cap.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

DYAI carries more volatility with a beta of 1.22 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

DYAI generates stronger free cash flow (-2M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dyadic International Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Dyadic International, Inc., a biotechnology platform company, develops, produces and sells enzymes and other proteins in the United States. The company is headquartered in Jupiter, Florida.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?